Roche (OTCMKTS:RHHBY) Stock Rating Cut to “Hold” at UBS Group

UBS Group downgraded shares of Roche (OTCMKTS:RHHBY) from a strong-buy rating to a hold rating in a research note issued to investors on Monday,Zacks reports.

A number of other equities analysts also recently commented on RHHBY. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “hold” rating to a “buy” rating in a report on Friday, October 23rd. Morgan Stanley upgraded shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price on the stock in a research report on Friday, August 7th. HSBC reissued a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Royal Bank Of Canada began coverage on shares of Roche in a research note on Tuesday, September 8th. They set an “outperform” rating for the company. Eight investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Roche currently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Roche Stock Performance

RHHBY opened at $59.18 on Monday. Roche has a fifty-two week low of $40.25 and a fifty-two week high of $61.49. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $55.70 and its two-hundred day moving average price is $53.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RHHBY. Opal Capital LLC acquired a new stake in shares of Roche during the 1st quarter worth about $4,448,000. S&CO Inc. boosted its position in Roche by 163.0% in the first quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after buying an additional 87,107 shares in the last quarter. Associated Banc Corp acquired a new position in Roche in the third quarter valued at about $1,740,000. North Star Asset Management Inc. acquired a new position in Roche in the second quarter valued at about $1,351,000. Finally, Puzo Michael J bought a new stake in Roche during the second quarter worth about $1,229,000.

About Roche

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.